907 related articles for article (PubMed ID: 15586364)
1. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
2. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE; Sciacca V; Iascone C
Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
[TBL] [Abstract][Full Text] [Related]
4. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
5. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study.
Ortner M-; Zumbusch K; Liebetruth J; Ebert B; Fleige B; Dietel M; Lochs H
Endoscopy; 2002 Aug; 34(8):611-6. PubMed ID: 12173080
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
7. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus.
Attwood SE; Lewis CJ; Caplin S; Hemming K; Armstrong G
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):258-63. PubMed ID: 15017666
[TBL] [Abstract][Full Text] [Related]
8. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
10. High-grade dysplasia in Barrett's oesophagus: natural history and review of clinical practice.
Thomas T; Richards CJ; de Caestecker JS; Robinson RJ
Aliment Pharmacol Ther; 2005 Mar; 21(6):747-55. PubMed ID: 15771761
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.
Kelty CJ; Ackroyd R; Brown NJ; Stephenson TJ; Stoddard CJ; Reed MW
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1289-96. PubMed ID: 15606390
[TBL] [Abstract][Full Text] [Related]
12. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
Morris CD; Byrne JP; Armstrong GR; Attwood SE
Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
[TBL] [Abstract][Full Text] [Related]
13. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up.
Ackroyd R; Kelty CJ; Brown NJ; Stephenson TJ; Stoddard CJ; Reed MW
Endoscopy; 2003 Jun; 35(6):496-501. PubMed ID: 12783347
[TBL] [Abstract][Full Text] [Related]
14. High power setting argon plasma coagulation for the eradication of Barrett's esophagus.
Pereira-Lima JC; Busnello JV; Saul C; Toneloto EB; Lopes CV; Rynkowski CB; Blaya C
Am J Gastroenterol; 2000 Jul; 95(7):1661-8. PubMed ID: 10925965
[TBL] [Abstract][Full Text] [Related]
15. Barrett's oesophagus--a pathologist's view.
Fléjou JF; Svrcek M
Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
[TBL] [Abstract][Full Text] [Related]
16. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication.
Guarner-Argente C; Buoncristiano T; Furth EE; Falk GW; Ginsberg GG
Gastrointest Endosc; 2013 Feb; 77(2):190-9. PubMed ID: 23317687
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy.
Schembre DB; Huang JL; Lin OS; Cantone N; Low DE
Gastrointest Endosc; 2008 Apr; 67(4):595-601. PubMed ID: 18279860
[TBL] [Abstract][Full Text] [Related]
19. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
20. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
